Evaluation of ST2 and IL-33 in Patients Presenting to the Emergency Department With Trouble Breathing

Evaluation of ST2 and IL-33 for Risk Stratification and Diagnosis in Patients Presenting to the Emergency Department With Dyspnea

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00707811

Enrollment

Registered

2008-07-01

Start date

2008-04-30

Completion date

2010-06-30

Last updated

2024-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma, Chronic Obstructive Pulmonary Disease, Congestive Heart Failure, Pneumonia, Pulmonary Embolism

Keywords

Dyspnea, Shortness of Breath, Trouble Breathing, ST2, IL-33

Brief summary

Trouble breathing (dyspnea) is a nonspecific symptom associated with many diseases such as chronic obstructive pulmonary disease (lung disorder in which the flow of air to the lungs is blocked), asthma, pneumonia, pulmonary hypertension (high blood pressure in the lungs), congestive heart failure (fluid build-up in the lungs because the heart is not pumping normally) and pulmonary embolism (blood clot in the lungs). The purpose of this study is to test two blood markers called ST2 and IL-33. Blood markers are proteins or other compounds in your blood that physicians use to diagnose different diseases and to determine what the course of an illness will be. In preliminary research studies, ST2 and IL-33 have been elevated in patients with a wide variety of diseases where the lungs are the primary organs involved. This research study will further investigate the ability of ST2 and IL-33 to predict the severity of disease and the possible use of ST2 and IL-33 in the diagnosis of various lung diseases.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Presenting to the Emergency Department with signs and symptoms of dyspnea (short of breath, tachypnea, hyperventilation, etc) within the last 24 hours * Normal cardiac output as measured by noninvasive bioimpedance * Greater than or equal to 18 years of age * Patient or legal representative willing and able to provide informed consent and comply with study procedures

Exclusion criteria

* ECG changes diagnostic of acute myocardial ischemia/infarction * Ischemic chest pain within the prior 24 hours by history * Obvious chest trauma

Design outcomes

Primary

Measure	Time frame
Any cause of mortality	180 days

Secondary

Measure	Time frame
Rehospitalization of a pulmonary etiology and/or significant lung morbidity (transplant, intubation, ARDS, pneumonia, pulmonary hypertension, etc)	180 days
Mortality with a pulmonary specific etiology	180 days
Any cause morbidity	180 days

Countries

United States

Outcome results